Epidemiology; diagnosis, and treatment of male hypogonadotropic hypogonadism
Abstract
Hypogonadotropic hypogonadism (HH), or secondary hypogonadism, is a clinical condition due to an impairment of the pituitary function, characterized by low testosterone plasma levels associated with normal or low FSH and LH plasma levels. An impairment of gonadotropin secretion and, therefore, a reduced efficiency of spermatogenesis was reported to be frequently associated to conditions different from the classical causes of secondary hypogonadism. These conditions (metabolic, endocrine and eating disorders, physical exercise etc.) have been associated with a non-classical form of HH that could be called "functional" HH (FHH). FHH differs from the classical one by the evidence that gonadotropin levels are in the low-normal range, but are inadequate for the testosterone levels, that often are also in the low-normal range. This commentary aims at reviewing knowledge on the forms of male HH in order to indicate and discuss clinical context, diagnostic and therapeutic approach in the less known non-classical form, i.e. FHH.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In case of a pituitary prolactinoma, treatment with dopamine agonists can be indicated and can result in normalization of testosterone levels and improvement of semen quality and libido.
“In case of a pituitary prolactinoma, treatment with dopamine agonists can be indicated and can result in normalization of testosterone levels and improvement of semen quality and libido [1,3,28,29,30].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [29]
Doses of hCG range from 1000 to 2000 IU 2 or 3 times a week.
“Doses of hCG range from 1000 to 2000 IU 2 or 3 times a week.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [29]
Doses of FSH preparations usually range between 75 to 150 IU 2 or 3 times a week.
“The doses of FSH preparations usually range between 75 to 150 IU 2 or 3 times a week [5,29].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [29]
Cites
Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice
Falardeau, J., Chung, W. C. J., Beenken, A., Raivio, T., Plummer, L., Sidis, Y., Jacobson-Dickman, E. E., Eliseenkova, A. V., Ma, J., Dwyer, A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34538 · Cited by 397 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Factors affecting spermatogenesis upon gonadotropin-replacement therapy: A meta-analytic study
Rastrelli, G., Corona, G., Mannucci, E., & Maggi, M. (2014) · Andrology · doi:10.1111/andr.262 · Cited by 211 · see citing works
Self-citationCorona, G., Rastrelli, G., & Maggi, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.002 · Cited by 177 · see citing works
Self-citationCorona, G., Rastrelli, G., Giagulli, V. A., Sila, A., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1358 · Cited by 105 · see citing works
Self-citationTreatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
Ide, V., Vanderschueren, D., & Antonio, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010021 · Cited by 101 · see citing works
Emerging medication for the treatment of male hypogonadism
Corona, G., Rastrelli, G., Vignozzi, L., & Maggi, M. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.683411 · Cited by 93 · see citing works
Self-citation
- Authors
- Lenzi, A., Balercia, G., Bellastella, A., Colao, A., Fabbri, A., Foresta, C., Galdiero, M., Gandini, L., Krausz, C., Lombardi, G., Lombardo, F., Maggi, M., Radicioni, A., Selice, R., Sinisi, A. A., & Forti, G.
- Affiliations
- Sapienza University of Rome (IT)
- Marche Polytechnic University (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- University of Naples Federico II (IT)
- University of Rome Tor Vergata (IT)
- University of Padua (IT)
- University of Florence (IT)
- Corresponding author
- Colao, A.
- ORCID
- Venue
- Journal of Endocrinological Investigation
- Published
- 2009-12
- Volume
- 32
- Issue
- 11
- Pages
- 934-938
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W2058688401
- Cited by
- 65
- References
- 1
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 4 · 2020: 6 · 2019: 1 · 2018: 5 · 2017: 4 · 2016: 4 · 2014: 4 · 2013: 4 · 2012: 3
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Endocrinological Investigation (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Health Sciences › Medicine › Reproductive Medicine › Sperm and Testicular Function
- Keywords
- male hypogonadotropic hypogonadism, secondary hypogonadism, androgen deficiency, gonadotropin secretion, FSH and LH, spermatogenesis, metabolic disorders, eating disorders, physical activity, diagnosis, treatment
- MeSH terms
- Adult, Child, Follicle Stimulating Hormone, Chorionic Gonadotropin, Humans, Hypogonadism, Male, Puberty, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review